With £60 million ($81.4 million) raised through recent share sales, the CDMO OXB has its eyes on a U.S. expansion. | The CDMO ...

FluMist has been approved since 2003, but, until last year, only for administration by a healthcare practitioner. The new nod ...

While it’s been easy to grow a bit desensitized to the seemingly unstoppable sales growth of Novo Nordisk and Eli Lilly’s | ...

The Department of Health and Human Services (HHS) is relaunching a task force focused on the safety of childhood vaccines. | ...

After a 54% year-over-year sales increase for CGRP migraine drug Vyepti in the U.S., Lundbeck has raised its peak sales projection for the therapy in the key market. | After a 54% year-over-year sales ...

The combination of Padcev and Keytruda delivered a phase 3 win in muscle-invasive bladder cancer. China did not renew the conditional approval for a controversial Alzheimer's disease drug. | The ...

For the first time, the FDA has approved a treatment for recurrent respiratory papillomatosis (RRP), a rare, chronic disease that causes benign tumors, most commonly in the voice box, and can force ...

With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

As President Donald Trump works to move sky-high U.S. drug prices closer to those in other developed countries, Eli Lilly ...

San Diego CDMO TriLink BioTechnologies is reducing its headcount while its parent company, Maravai LifeSciences, moves ...

President Donald Trump’s announcement about tariffs on pharmaceutical goods imported to the United States is delayed. | ...

Chinese authorities did not renew a conditional approval of Green Valley Pharmaceuticals’ controversial Alzheimer’s disease ...